EA200300028A1 - Лечение и профилактика состояний, ассоциированных с сердечной инсулинорезистентностью - Google Patents

Лечение и профилактика состояний, ассоциированных с сердечной инсулинорезистентностью

Info

Publication number
EA200300028A1
EA200300028A1 EA200300028A EA200300028A EA200300028A1 EA 200300028 A1 EA200300028 A1 EA 200300028A1 EA 200300028 A EA200300028 A EA 200300028A EA 200300028 A EA200300028 A EA 200300028A EA 200300028 A1 EA200300028 A1 EA 200300028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin resistance
conditions associated
prevention
treatment
pharmaceutically acceptable
Prior art date
Application number
EA200300028A
Other languages
English (en)
Russian (ru)
Inventor
Амит Натвани
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200300028A1 publication Critical patent/EA200300028A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200300028A 2000-06-16 2000-06-16 Лечение и профилактика состояний, ассоциированных с сердечной инсулинорезистентностью EA200300028A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
EA200300028A1 true EA200300028A1 (ru) 2003-04-24

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300028A EA200300028A1 (ru) 2000-06-16 2000-06-16 Лечение и профилактика состояний, ассоциированных с сердечной инсулинорезистентностью

Country Status (15)

Country Link
EP (1) EP1292301A1 (hu)
JP (1) JP2004503499A (hu)
CN (1) CN1592620A (hu)
AP (1) AP2002002688A0 (hu)
BG (1) BG107384A (hu)
BR (1) BR0017254A (hu)
CA (1) CA2436116A1 (hu)
DZ (1) DZ3389A1 (hu)
EA (1) EA200300028A1 (hu)
HU (1) HUP0301103A2 (hu)
IL (1) IL153452A0 (hu)
MX (1) MXPA02012619A (hu)
NO (1) NO20026000L (hu)
WO (1) WO2001095906A1 (hu)
YU (1) YU1203A (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Also Published As

Publication number Publication date
YU1203A (sh) 2006-05-25
JP2004503499A (ja) 2004-02-05
CN1592620A (zh) 2005-03-09
NO20026000L (no) 2003-02-11
IL153452A0 (en) 2003-07-06
MXPA02012619A (es) 2003-04-10
WO2001095906A1 (en) 2001-12-20
NO20026000D0 (no) 2002-12-13
CA2436116A1 (en) 2001-12-20
AP2002002688A0 (en) 2002-12-31
BR0017254A (pt) 2004-01-06
EP1292301A1 (en) 2003-03-19
DZ3389A1 (fr) 2001-12-20
BG107384A (bg) 2003-09-30
HUP0301103A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
DOP2004001052A (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
AR093609A2 (es) Compuesto amorfo de benzimidazol, composicion farmaceutica que lo comprende y metodo para tratar o prevenir la ulcera gastrica
NL300282I1 (nl) Nieuwe exendineagonistformuleringen en werkwijze voor toediening daarvan.
EA200400305A1 (ru) 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
Eriksson et al. Dabigatran etexilate.
ATE309999T1 (de) Blutplättchen-adp-rezeptor-inhibitoren
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
EA200101089A1 (ru) Новый способ лечения
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
CR11037A (es) Derivados de 4-tetrazolil -4fenilpiperidina para tratar el dolor (divisional)
ATE464905T1 (de) Phosphattransporthemmer
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EA200101133A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
WO2001052847A8 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
AU2001285807A1 (en) Acidic treatment liquid and method of treating copper surfaces
BR0101090A (pt) Composição para administração parenteral, e, método para prevenção ou tratamento de infecções ou infestações por helmintos, acarìdeos ou artrópodo endo- ou ectoparasìticos em um animal de sangue quente
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
EA199800139A1 (ru) Способ лечения аденомы толстой кишки
Gillen et al. Problems associated with the clinical use of proton pump inhibitors
EA200300028A1 (ru) Лечение и профилактика состояний, ассоциированных с сердечной инсулинорезистентностью
MX9805512A (es) Un aparato para colocacion de escuadra en salientes de conducto de ventilacion.
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
ES2148561T3 (es) Prevencion y curacion de enfermedades alergicas de tipo i.